Brett Guthrie
Representative for Kentucky · Republican · United States
“(d) Study on Long-Term Symptoms or Conditions Related to Traumatic Brain Injury.-- (1) In general.--The Secretary, in consultation with stakeholders and the heads of other relevant Federal departments and agencies, as appropriate, shall conduct, either directly or through a contract with a nonprofit private entity, a study to-- (A) examin…”
“(d) Study on Long-Term Symptoms or Conditions Related to Traumatic Brain Injury.-- (1) In general.--The Secretary, in consultation with stakeholders and the heads of other relevant Federal departments and agencies, as appropriate, shall conduct, either directly or through a contract with a nonprofit private entity, a study to-- (A) examin…”
“300n-5(a))-- (A) by striking ``2011, and'' and inserting ``2011,''; and (B) by inserting ``, and $235,500,000 for each of fiscal years 2026 through 2030'' before the period at the end.”
“300n-5(a))-- (A) by striking ``2011, and'' and inserting ``2011,''; and (B) by inserting ``, and $235,500,000 for each of fiscal years 2026 through 2030'' before the period at the end.”
“360aa note) is amended-- (1) in the section heading, by striking ``als and other rare neurodegenerative disease action plan'' and inserting ``fda rare neurodegenerative disease action plan''; and (2) by adding at the end the following: ``(c) FDA Rare Neurodegenerative Disease Action Plan.-- ``(1) In general.--Not later than 18 months afte…”
“360aa note) is amended-- (1) in the section heading, by striking ``als and other rare neurodegenerative disease action plan'' and inserting ``fda rare neurodegenerative disease action plan''; and (2) by adding at the end the following: ``(c) FDA Rare Neurodegenerative Disease Action Plan.-- ``(1) In general.--Not later than 18 months afte…”
The complete record
Every one of 330 lines we hold for Brett Guthrie, in date order, each linked to its source. Free to read, in full, without an account. Page 1 of 7.
“Mr. Speaker, I object to the vote on the ground that a quorum is not present and make the point of order that a quorum is not present. The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, further proceedings on this question will be postponed. The point of no quorum is considered withdrawn. ____________________”
“Mr. Speaker, I yield myself the balance of my time to close. Mr. Speaker, in closing, I will mention Brian and Sandra testified before our committee. When I was first elected to Congress, the Ensor family from Bullitt County, Kentucky, came to see me, and I got to know Mitch. I went to his funeral services, unfortunately. I was touched by his family, which is why this bill is important to me. Mr. Speaker, I strongly encourage everybody to vote for this bill. There may be a procedural call on this bill. This bill will pass this week. I look forward to seeing it pass, being sent to the Senate, and hopefully signed into law very soon. Mr. Speaker, I yield back the balance of my time.”
“Speaker, I want to take a moment to let them know that I recognize their resilience and their commitment to a better future for themselves and other patients with ALS. Mr. Speaker, I want them to know that I stand with them, and I ask that my colleagues do the same. Mr. Speaker, I encourage my colleagues to support this bill, and I reserve the balance of my time.”
“Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 8205 led by my colleagues, Representative Quigley and Representative Calvert. H.R. 8205 reauthorizes the Accelerating Access to Critical Therapies for ALS Reauthorization Act, which has supported critical research and development for ALS therapies. The ACT for ALS program has worked to expand access to key therapies for both individuals with ALS and those with other rare neurodegenerative conditions. It is imperative that we pass this bill today to continue advancing research and therapeutic development in the fight against this disease. To my fellow Americans living with ALS and their caregivers, Mr.”
“Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks on the legislation and to include extraneous material on H.R. 8205. The SPEAKER pro tempore. Is there objection to the request of the gentleman from Kentucky? There was no objection.”
“``(2) Report.--Not later than 5 years after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration a report that describes the actions taken by the Food and Drug Administration under the action plan published under paragraph (1) and the extent to which such action plan meets the requirements specified in paragraph (1).''. The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Kentucky (Mr. Guthrie) and the gentlewoman from Colorado (Ms. DeGette) each will control 20 minutes. The Chair recognizes the gentleman from Kentucky. General Leave”
“360aa note) is amended-- (1) in the section heading, by striking ``als and other rare neurodegenerative disease action plan'' and inserting ``fda rare neurodegenerative disease action plan''; and (2) by adding at the end the following: ``(c) FDA Rare Neurodegenerative Disease Action Plan.-- ``(1) In general.--Not later than 18 months after the date of enactment of the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026, the Commissioner of Food and Drugs shall publish on the website of the Food and Drug Administration an action plan that includes a description of the actions that the Food and Drug Administration intends to take during the 5-year period following publication of the action plan with respect to the program enhancements, policy development, regulatory science initiatives, and other appropriate initiatives described in subsection (a).”
“360ee note) is amended by adding at the end the following: ``(4) The term `phase 3', with respect to a clinical trial, includes a phase 2/3 combined trial that begins enrollment within a timeframe, determined by the Secretary through the terms and conditions of the grant awarded under this section.''. SEC. 4. FDA RARE NEURODEGENERATIVE DISEASE ACTION PLAN. Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C.”
“360ee note) is amended-- (1) in paragraph (2)(B), by striking ``and'' at the end; (2) in paragraph (3), by striking the period at the end and inserting ``; and''; and (3) by adding at the end the following: ``(4) the entity seeking such grant will promptly report any new and serious adverse events and safety information that is considered to be unexpected with respect to the phase 3 trial to the grant-making institution, in addition to complying with the safety reporting requirements under section 312.32 of title 21, Code of Federal Regulations (or any successor regulations).''. (c) Clarifying Participating Clinical Trial Definition.-- Section 2(e) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C.”
“360ee note) is amended by adding at the end the following: ``(4) Renewal of grants for research on therapies for als review.--In reviewing applications for renewals of a grant awarded under this section with respect to an investigational drug, the Secretary shall request from the manufacturer or sponsor, and assess, the enrollment, safety, and any available efficacy data relating to the investigational drug in the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis.''. (b) Reporting Safety Data.--Section 2(c) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C.”
“(b) Grants for ALS Research.--Section 2(f) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C. 360ee note) is amended by striking ``2026'' and inserting ``2031''. SEC. 3. IMPROVEMENTS TO PROGRAM FOR GRANTS FOR RESEARCH ON THERAPIES FOR ALS. (a) Renewal of Grants for Research on Therapies for ALS Review.--Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C.”
“Mr. Speaker, I move to suspend the rules and pass the bill [[Page H4653]] (H.R. 8205) to amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes, as amended. The Clerk read the title of the bill. The text of the bill is as follows: H.R. 8205 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026''. SEC. 2. REAUTHORIZATION OF ACCELERATING ACCESS TO CRITICAL THERAPIES FOR ALS ACT. (a) In General.--Section 7 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117-79) is amended by striking ``2026'' and inserting ``2031''.”
“Mr. Speaker, I yield myself such time as I may consume. [[Page H4652]] Mr. Speaker, I yield 5 minutes to the gentleman from Pennsylvania (Mr. Fitzpatrick), my good friend. He is a member of the Ways and Means and Intel Committees and is really passionate about these issues. My friend from Colorado has touched on this. It is something that we absolutely have to get to the bottom of. I am very thankful for the leadership of the gentlewoman from Illinois and the gentleman from Pennsylvania.”
“Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 6238, led by my colleagues Representatives Underwood and Fitzpatrick, which authorizes the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone Initiative within the National Institutes of Health. According to CDC estimates, more than 80 percent of the pregnancy- related deaths and roughly half of the severe maternal morbidity events could be prevented. That is why it is so essential for us to advance the IMPROVE Initiative, which supports research into identifying and reducing preventable causes of maternal death and ways to improve maternal health outcomes. Mr. Speaker, I encourage my colleagues to support this bill, and I reserve the balance of my time.”
“Mr. Speaker, I ask unanimous consent that all Members have 5 legislative days to revise and extend their remarks on the legislation and include extraneous material on H.R. 6238. The SPEAKER pro tempore. Is there objection to the request of the gentleman from Kentucky? There was no objection.”
“``(c) Implementation.--The Director of NIH may award grants or enter into contracts, cooperative agreements, or other transactions to carry out this section. ``(d) Authorization of Appropriations.--There is authorized to be appropriated to carry out this section $63,400,000 for each of fiscal years 2026 through 2030.''. The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Kentucky (Mr. Guthrie) and the gentlewoman from Colorado (Ms. DeGette) each will control 20 minutes. The Chair recognizes the gentleman from Kentucky. general leave”
“``(b) Objectives.--The Initiative shall-- ``(1) advance research to-- ``(A) reduce preventable causes of maternal mortality and severe maternal morbidity; ``(B) reduce health disparities related to maternal health outcomes, including such disparities associated with populations with disproportionately high rates of maternal mortality and severe maternal morbidity relative to the national rate; and ``(C) improve health for pregnant and postpartum women before, during, and after pregnancy; ``(2) use an integrated approach to understand the factors, including biological, behavioral, and other factors, that affect maternal mortality and severe maternal morbidity by building an evidence base for improved outcomes in specific regions of the United States; and ``(3) target health disparities associated with maternal mortality and severe maternal morbidity by-- ``(A) implementing and evaluating community-based interventions for disproportionately affected women; and ``(B) identifying risk factors and the underlying biological mechanisms associated with leading causes of maternal mortality and severe maternal morbidity in the United States.”
“``(a) In General.--The Director of NIH shall continue to carry out a program to improve maternal health outcomes, to be known as the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone Initiative or the `IMPROVE Initiative' (referred to in this section as the `Initiative').”
“Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 6238) to establish the IMPROVE Initiative within the National Institutes of Health, as amended. The Clerk read the title of the bill. The text of the bill is as follows: H.R. 6238 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``NIH Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone Act'' or the ``NIH IMPROVE Act''. SEC. 2. IMPROVE INITIATIVE. Part B of title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by adding at the end the following: ``SEC. 409K. IMPROVE INITIATIVE.”
“Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise in strong support of H.R. 3491, led by my colleagues Representatives DeGette and Hudson. This bill would authorize the INCLUDE Project at the National Institutes of Health, which advances research into Down syndrome to improve the health and quality of life of individuals with Down syndrome and their families. This project investigates conditions that affect people with Down syndrome, as well as the general public, with a hope of improving our understanding of the condition and advancing the quality-of-life outcomes for individuals with Down syndrome and patients facing similar medical issues. I encourage my colleagues to support this bill, and I reserve the balance of my time. {time} 1600”
“Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks on the legislation and include extraneous material on H.R. 3491. The SPEAKER pro tempore. Is there objection to the request of the gentleman from Kentucky? There was no objection.”
“``(2) Contents.--Each report under paragraph (1) shall include-- ``(A) identification of the institute or center involved; ``(B) a statement of whether the research is or was being carried out directly by such institute or center or by multiple institutes and centers; and ``(C) identification of any resulting real-world evidence that is or may be used for clinical research and medical care for patients with Down syndrome.''. The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Kentucky (Mr. Guthrie) and the gentlewoman from Colorado (Ms. DeGette) each will control 20 minutes. The Chair recognizes the gentleman from Kentucky. General Leave”
“``(e) Biennial Reports to Congress.-- ``(1) In general.--The Director of NIH shall submit, on a biennial basis, to the Committee on Energy and Commerce and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the House of Representatives and the Committee on Health, Education, Labor, and Pensions and the Subcommittee on Labor, Health and Human Services, Education, and Related Agencies of the Committee on Appropriations of the Senate, a report that catalogs the research conducted or supported under this section.”
“``(d) Consultation With Stakeholders.--In carrying out activities under this section, the Director of NIH shall, as appropriate and to the maximum extent feasible, consult with relevant stakeholders, including patient advocates, to ensure that such activities take into consideration the needs of individuals with Down syndrome.”
“``(c) Coordination; Prioritizing Nonduplicative Research.-- The Director of NIH shall ensure that-- ``(1) the programs and activities of the institutes and centers of the National Institutes of Health relating to Down syndrome and co-occurring conditions are coordinated, including through the Office of the Director of NIH and priority-setting reviews conducted pursuant to section 402(b)(3); and ``(2) such institutes and centers, prioritize, as appropriate, Down syndrome research that does not duplicate existing research activities of the National Institutes of Health.”
“``(b) Program Elements.--The program under subsection (a) shall include-- ``(1) high-risk, high-reward research on the effects of trisomy 21 on human development and health; ``(2) promoting research for participants with Down syndrome across the lifespan, including cohort studies to facilitate improved understanding of Down syndrome and co- occurring conditions and development of new interventions; ``(3) expanding the number of clinical trials that are inclusive of, or expressly for, participants with Down syndrome, including novel biomedical and pharmacological interventions and other therapies designed to promote or enhance activities of daily living; ``(4) research on the biological mechanisms in individuals with Down syndrome pertaining to structural, functional, and behavioral anomalies and dysfunction as well as stunted growth; ``(5) supporting research to improve diagnosis and treatment of conditions co-occurring with Down syndrome, including the identification of biomarkers related to risk factors, diagnosis, and clinical research and therapeutics; ``(6) research on the causes of increased prevalence, and concurrent treatment, of co-occurring conditions, such as Alzheimer's disease and related dementias and autoimmunity, in individuals with Down syndrome; and ``(7) research, training, and investigation on improving the quality of life of individuals with Down syndrome and their families.”
“``(a) In General.--The Director of NIH shall carry out a program of research, training, and investigation related to Down syndrome to be known as the `INvestigation of Co- occurring conditions across the Lifespan to Understand Down syndromE Project' or the `INCLUDE Project'.”
“Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 3491) to amend the Public Health Service Act to authorize the Secretary of Health and Human Services to carry out a program of research, training, and investigation related to Down syndrome, and for other purposes. The Clerk read the title of the bill. The text of the bill is as follows: H.R. 3491 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, [[Page H4650]] SECTION 1. SHORT TITLE. This Act may be cited as the ``DeOndra Dixon INCLUDE Project Act of 2025''. SEC. 2. DEONDRA DIXON INCLUDE PROJECT. Part B of title IV of the Public Health Service Act (42 U.S.C. 284 et seq.) is amended by adding at the end the following: ``SEC. 409K. DOWN SYNDROME RESEARCH.”
“Mr. Speaker, on that I demand the yeas and nays. The yeas and nays were ordered. The SPEAKER pro tempore. Pursuant to clause 8 of rule XX, further proceedings on this motion will be postponed. ____________________”
“Mr. Speaker, in closing, I encourage a ``yes'' vote on this bill, and I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Kentucky (Mr. Guthrie) that the House suspend the rules and pass the bill, H.R. 4541, as amended. The question was taken. The SPEAKER pro tempore. In the opinion of the Chair, two-thirds being in the affirmative, the ayes have it.”
“Mr. Speaker, I commend my colleague. I know he talked about his mom and his sister, but as we all know, those of us who have been here a little bit of time, his brother was our colleague and had cancer as well. We miss him. May God bless his family. Mr. Speaker, I reserve the balance of my time.”
“Mr. Speaker, I yield 4 minutes to the gentleman from Pennsylvania (Mr. Fitzpatrick), my good friend and a member of the Ways and Means Committee.”
“The EARLY Act has played a significant role in increasing breast cancer awareness and prevention efforts, and we must vote today to ensure future generations of women continue to benefit from these efforts. Mr. Speaker, I encourage my colleagues to support this bill, and I reserve the balance of my time.”
“Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 4541, led by my colleagues Representatives Wasserman Schultz and Miller-Meeks. This bill reauthorizes funding for the Young Women's Breast Health Education and Awareness Requires Learning Young Act, which supports critical education, outreach, and provider training efforts through HHS, acting through the CDC to close the gaps between screening and detection of breast cancer in women under the age of 45 and those at high risk. Breast cancer is the second most common cancer and second leading cause of cancer death among American women, claiming the lives of roughly 42,000 women annually.”
“Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks on the legislation and to include extraneous material on H.R. 4541. The SPEAKER pro tempore. Is there objection to the request of the gentleman from Kentucky? There was no objection.”
“The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Kentucky (Mr. Guthrie) and the gentlewoman from Colorado (Ms. DeGette) each will control 20 minutes. The Chair recognizes the gentleman from Kentucky. General Leave”
“300n-5(a))-- (A) by striking ``2011, and'' and inserting ``2011,''; and (B) by inserting ``, and $235,500,000 for each of fiscal years 2026 through 2030'' before the period at the end. (b) GAO Study.--Not later than September 30, 2027, the Comptroller General of the United States shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on the work of the National Breast and Cervical Cancer Early Detection Program, including-- (1) an estimate of the number of individuals eligible for services provided under such program; (2) a summary of trends in the number of individuals served through such program; and (3) an assessment of any factors that may be driving the trends identified under paragraph (2), including any barriers to accessing breast and cervical cancer screenings provided by such program.”
“300n-4(b))-- (A) by striking ``1 year after the date of the enactment of the National Breast and Cervical Cancer Early Detection Program Reauthorization of 2007, and annually thereafter,'' and inserting ``2 years after the date of enactment of the SCREENS for Cancer Act of 2025, and every 5 years thereafter,''; (B) by striking ``Labor and Human Resources'' and inserting ``Health, Education, Labor, and Pensions''; and (C) by striking ``preceding fiscal year'' and inserting ``preceding 2 fiscal years in the case of the first report after the date of enactment of the SCREENS for Cancer Act of 2025, and preceding 5 fiscal years for each report thereafter,''; and (4) in section 1510(a) (42 U.S.C.”
“300m)-- (A) in subsection (a)-- (i) in paragraph (1), by striking ``that, initially'' and all that follows through the semicolon and inserting ``that appropriate breast and cervical cancer screening and diagnostic services are provided consistent with relevant evidence-based recommendations; and''; (ii) by striking paragraphs (2) and (4); (iii) by redesignating paragraph (3) as paragraph (2); and (iv) in paragraph (2), as so redesignated, by striking ``; and'' and inserting a period; and (B) by striking subsection (d); (3) in section 1508(b) (42 U.S.C.”
“300k)-- (A) in subsection (a)-- (i) in paragraph (2), by striking ``the provision of appropriate follow-up services and support services such as case management'' and inserting ``that appropriate follow-up services are provided''; (ii) in paragraph (3), by striking ``programs for the detection and control'' and inserting ``programs for the prevention, detection, and control''; (iii) in paragraph (4), by striking ``the detection and control'' and inserting ``the prevention, detection, and control''; (iv) in paragraph (5)-- (I) by striking ``monitor'' and inserting ``ensure''; and (II) by striking ``; and'' and inserting a semicolon; (v) by redesignating paragraph (6) as paragraph (9); (vi) by inserting after paragraph (5) the following: ``(6) to enhance appropriate support activities to increase breast and cervical cancer screenings, such as navigation of health care services, implementation of evidence-based or evidence-informed strategies to increase breast and cervical cancer screening in health care settings, and facilitation of access to health care settings; ``(7) to reduce disparities in breast and cervical cancer incidence, morbidity, and mortality, including in populations with higher than average rates; ``(8) to improve access to breast and cervical cancer screening and diagnostic services and reduce related barriers, including factors that relate to negative health outcomes; and''; and (vii) in paragraph (9), as so redesignated, by striking ``through (5)'' and inserting ``through (8)''; and (B) by striking subsection (d); (2) in section 1503 (42 U.S.C.”
“This title may be cited as the ``Screening for Communities to Receive Early and Equitable Needed Services for Cancer Act of 2025'' or the ``SCREENS for Cancer Act of 2025''. SEC. 202. NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM. (a) National Breast and Cervical Cancer Early Detection Program.--Title XV of the Public Health Service Act (42 U.S.C. 300k et seq.) is amended-- (1) in section 1501 (42 U.S.C.”
“Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 4541) to reauthorize the Young Women's Breast Health Education and Awareness Requires Learning Young Act of 2009, as amended. The Clerk read the title of the bill. The text of the bill is as follows: H.R. 4541 Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, TITLE I--EARLY ACT REAUTHORIZATION SEC. 101. SHORT TITLE. This title may be cited as the ``EARLY Act Reauthorization of 2025''. SEC. 102. REAUTHORIZATION OF THE YOUNG WOMEN'S BREAST HEALTH EDUCATION AND AWARENESS REQUIRES LEARNING YOUNG ACT OF 2009. Section 399NN(h) of the Public Health Service Act (42 U.S.C. 280m(h)) is amended by striking ``2026'' and inserting ``2031''. TITLE II--SCREENS FOR CANCER ACT SEC. 201. SHORT TITLE.”
“Mr. Speaker, in closing, I encourage a ``yes'' vote on this bill, and I yield back the balance of my time. The SPEAKER pro tempore. The question is on the motion offered by the gentleman from Kentucky (Mr. Guthrie) that the House suspend the rules and pass the bill, H.R. 1493, as amended. The question was taken; and (two-thirds being in the affirmative) the rules were suspended and the bill, as amended, was passed. A motion to reconsider was laid on the table. ____________________”
“Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise today in strong support of H.R. 1493, led by my colleagues Representatives Pallone and Bacon, which would reauthorize HHS programs that allocate resources for traumatic brain injury prevention, improving access to TBI rehabilitation and TBI patient advocacy systems. TBI is a significant public health burden and a major driver of death and disability. In 2021 alone, there were over 69,000 TBI-related deaths. Though we may make every effort to prevent TBI from occurring in the first place, it is critical that when a TBI occurs, we are prepared and ready to employ resources that support patients in their recovery and rehabilitation. Mr. Speaker, I encourage my colleagues to support this bill, and I reserve the balance of my time.”
“Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days to revise and extend their remarks on the legislation and to include extraneous material on H.R. 1493. The SPEAKER pro tempore. Is there objection to the request of the gentleman from Kentucky? There was no objection. {time} 1540”
“(2) Public report.--Not later than 2 years after the date of enactment of this Act, the Secretary shall-- (A) submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report detailing the findings, conclusions, and recommendations of the study described in paragraph (1); and (B) in the case that such study is conducted directly by the Secretary, make the report described in subparagraph (A) publicly available on the website of the Department of Health and Human Services. The SPEAKER pro tempore. Pursuant to the rule, the gentleman from Kentucky (Mr. Guthrie) and the gentleman from New Jersey (Mr. Pallone) each will control 20 minutes. The Chair recognizes the gentleman from Kentucky. General Leave”
“(d) Study on Long-Term Symptoms or Conditions Related to Traumatic Brain Injury.-- (1) In general.--The Secretary, in consultation with stakeholders and the heads of other relevant Federal departments and agencies, as appropriate, shall conduct, either directly or through a contract with a nonprofit private entity, a study to-- (A) examine the incidence and prevalence of long-term or chronic symptoms or conditions in individuals who have experienced a traumatic brain injury; (B) examine the evidence base of research related to the chronic effects of traumatic brain injury across the lifespan; (C) examine any correlations between traumatic brain injury and increased risk of other conditions, such as dementia and mental health conditions; (D) assess existing services available for individuals with such long-term or chronic symptoms or conditions; and (E) identify any gaps in research related to such long-term or chronic symptoms or conditions of individuals who have experienced a traumatic brain injury.”
“10284); (2) an outline of existing surveys and activities of the Centers for Disease Control and Prevention on traumatic brain injuries and any steps the agency has taken to address gaps in data collection related to such higher risk populations, which may include leveraging surveys such as the National Intimate Partner and Sexual Violence Survey to collect data on traumatic brain injuries; (3) an overview of any outreach or education efforts to reach such higher risk populations; and (4) any challenges associated with reaching such higher risk populations.”
“(c) Report to Congress.--Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this Act as the ``Secretary'') shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that contains-- (1) an overview of populations who may be at higher risk for traumatic brain injury, such as individuals affected by domestic violence or sexual assault and public safety officers as defined in section 1204 of the Omnibus Crime Control and Safe Streets Act of 1968 (34 U.S.C.”
“(2) State grants for protection and advocacy services.-- Section 1253 of the Public [[Page H4647]] Health Service Act (42 U.S.C. 300d-53) is amended by striking subsection (l). (3) Authorization of appropriations.--Part E of title XII of the Public Health Service Act (42 U.S.C. 300d-51 et seq.) is amended by inserting after section 1253 (42 U.S.C. 300d- 53) the following: ``SEC. 1253A. AUTHORIZATION OF APPROPRIATIONS FOR STATE PROGRAMS RELATING TO TRAUMATIC BRAIN INJURY. ``There are authorized to be appropriated to carry out sections 1252 and 1253 $13,118,000 for each of fiscal years 2026 through 2030.''.”